| Ytd | -64.00% | |
| 1y | -45.47% |
| Open | 4.47 | Prev Close | 4.47 | Low | 4.37 | High | 4.53 | Mkt Cap | 229.60M |
| Vol | 0.00 | Avg Vol | 955.07K | EPS | 1.44 | P/E | 3.09 | Forward P/E | 2.73 |
| Beta | 1.57 | Short Ratio | 4.54 | Inst. Own | 60.02% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 04-30 | 50-d Avg | 7.77 | 200-d Avg | 9.51 | 1yr Est | 12.00 |
EBS News
Emergent BioSolutions cut FY2026 revenue guidance to $645-$675 million after reaffirming a $720-$760
HC Wainwright & Co. analyst Raghuram Selvaraju maintains Emergent BioSolutions (NYSE:EBS) wit
Emergent Biosolutions NYSE: EBS reported second-quarter 2026 revenue and adjusted EBITDA above its p
Emergent BioSolutions Inc. (EBS) Q2 2026 Earnings Call Transcript
Gainers Creative Medical Tech (NASDAQ:CELZ) stock increased by 107.8% to $1.39 during Thursday'
Gainers Creative Medical Tech (NASDAQ:CELZ) stock moved upwards by 31.4% to $0.88 during Wednesday&
Emergent BioSolutions (NYSE:EBS) sees Q3 sales of $110.000 million-$130.000 million vs $209.000 mill
Emergent BioSolutions (NYSE:EBS) lowers FY2026 sales outlook from $720.000 million-$760.000 million
GAITHERSBURG, Md. , Aug. 05, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions (NYSE: EBS), a global bi
Second Quarter 2026 Total Revenues of $234. 3 million, an improvement of 66% versus prior year Secon
GAITHERSBURG, Md., July 22, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) will hos
Emergent BioSolutions (NYSE:EBS) today announced it has been awarded a contract modification valued
GAITHERSBURG, Md., June 29, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions (NYSE:EBS) today announce
AKRON, Ohio--(BUSINESS WIRE)-- #BIO2026--BioMendics, LLC, a clinical-stage biotechnology company dev
https://www.fda.gov/news-events/press-announcements/fda-broadens-access-over-counter-naloxone-nasal-
Emergent BioSolutions Inc. (EBS) Presents at Goldman Sachs 47th Annual Global Healthcare Conference
Efforts focus on increasing awareness, expanding access to lifesaving NARCAN® Nasal Spray and reachi
Emergent BioSolutions Inc. (NYSE:EBS) today announced it has been awarded a contract modification va
![Emergent BioSolutions Receives $64.5 Million Contract Modification for BAT® [Botulism Antitoxin Heptavalent (A, B, C, D, E, F, G) – (Equine)] to Support U.S. Biodefense Strategy](https://images.financialmodelingprep.com/news/emergent-biosolutions-receives-645-million-contract-modification-for-bat-20260528.jpg)
GAITHERSBURG, Md., May 28, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today ann
GAITHERSBURG, Md., May 20, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) announced
https://www.cdc.gov/ebola/situation-summary/index.html
Emergent BioSolutions (NYSE:EBS), a global biodefense company, today announced that the Saudi Food a
![Emergent BioSolutions Receives Saudi Food and Drug Authority Approval for ACAM2000® [Smallpox and Mpox (Vaccinia) Vaccine, Live]](https://images.financialmodelingprep.com/news/emergent-biosolutions-receives-saudi-food-and-drug-authority-approval-20260518.jpg)
GAITHERSBURG, Md., May 18, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions (NYSE:EBS), a global biode
Several pharmaceutical stocks are rising in premarket trading in the wake of a hantavirus outbreak.
Emergent BioSolutions Inc. (EBS) Q1 2026 Earnings Call Transcript
Emergent BioSolutions (NYSE:EBS) sees Q2 sales of $170.000 million-$185.000 million vs $186.000 mill
Emergent BioSolutions (NYSE:EBS) affirms FY2026 sales outlook from $720.000 million-$760.000 million
Emergent BioSolutions (NYSE:EBS) reported quarterly earnings of $0.21 per share which beat the analy
GAITHERSBURG, Md., April 30, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today r
Emergent BioSolutions Inc. (NYSE:EBS) today announced that Singapore's Health Sciences Authority
GAITHERSBURG, Md., April 30, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today a
The executed agreement is valued at approximately $50 million, of which $36 million is contingent on
GAITHERSBURG, Md., April 29, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today a
Emergent BioSolutions Inc. (NYSE:EBS) today announced it has entered into an agreement with Substiph
Emergent BioSolutions (NYSE:EBS) announced that it has partnered with the B.C. Provincial Health Ser
Emergent BioSolutions Inc. (NYSE: EBS) today announced it has secured a contract award valued at app
HC Wainwright & Co. analyst Raghuram Selvaraju maintains Emergent BioSolutions (NYSE:EBS) wit
U.S. stocks down mid-trading, Nasdaq falls 1%. Dow down 1.40%, S&P 500 falls 0.74%. Dell shares
US stocks traded lower, Dow down 600 points. Nasdaq and S&P also fell. Consumer staples up, tech
Emergent BioSolutions (NYSE:EBS) sees FY2026 sales of $720.000 million-$760.000 million vs $1.155 bi
Emergent BioSolutions (NYSE:EBS) reported quarterly losses of $(0.43) per share which missed the ana